23-Feb-2026
Globe Newswire (Tue, 3-Feb 7:01 AM ET)
Globe Newswire (Thu, 22-Jan 7:01 AM ET)
Globe Newswire (Tue, 20-Jan 7:01 AM ET)
Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights
Globe Newswire (Thu, 8-Jan 7:01 AM ET)
Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
Globe Newswire (Tue, 23-Dec 7:05 AM ET)
Globe Newswire (Tue, 23-Dec 7:01 AM ET)
Invivyd to Participate at the 8th Annual Evercore Healthcare Conference
Globe Newswire (Tue, 25-Nov 7:01 AM ET)
Globe Newswire (Mon, 24-Nov 7:01 AM ET)
IVVD Secures FDA Clearance for COVID Antibody Trials, Paving Way for Novel Prevention Approach
Market Chameleon (Mon, 6-Oct 7:23 AM ET)
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
Invivyd trades on the NASDAQ stock market under the symbol IVVD.
As of February 23, 2026, IVVD stock price climbed to $1.61 with 1,251,124 million shares trading.
IVVD has a beta of 2.08, meaning it tends to be more sensitive to market movements. IVVD has a correlation of 0.07 to the broad based SPY ETF.
IVVD has a market cap of $454.00 million. This is considered a Small Cap stock.
Last quarter Invivyd reported $13 million in Revenue and -$.06 earnings per share. This fell short of revenue expectation by $-1 million and exceeded earnings estimates by $.02.
In the last 3 years, IVVD traded as high as $5.20 and as low as $.35.
The top ETF exchange traded funds that IVVD belongs to (by Net Assets): VTI, XBI, VXF, ITOT, PRFZ.
IVVD has outperformed the market in the last year with a price return of +33.1% while the SPY ETF gained +13.0%. However, in the short term, IVVD had mixed performance relative to the market. It has underperformed in the last 3 months, returning -32.9% vs +4.9% return in SPY. But in the last 2 weeks, IVVD shares have fared better than the market returning +1.3% compared to SPY -1.2%.
IVVD support price is $1.45 and resistance is $1.65 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IVVD shares will trade within this expected range on the day.